Lv3
360 积分 2024-11-04 加入
Empagliflozin attenuates renal damage in diabetic nephropathy by modulating mitochondrial quality control via Prdx3-PINK1 pathway
15天前
已完结
Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/Parkin Pathway to Alleviate ISO-induced Cardiac Remodeling
15天前
已完结
Dapagliflozin alleviates isoprenaline-induced cardiac hypertrophy by promoting mitophagy via AMPKα2 signaling pathway
15天前
已完结
Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states
22天前
已完结
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
4个月前
已完结
A systematic review and meta-analysis comparing the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 agonists in type 2 diabetes
5个月前
已完结
Cardiorenal effects of therapies for type 2 diabetes and obesity
6个月前
已关闭
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
6个月前
已完结
Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials
6个月前
已完结
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
6个月前
已完结
皖公网安备34019202002308
